J Brandt

Summary

Country: Germany

Publications

  1. ncbi Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
    J Braun
    Department of Rheumatology, Benjamin Franklin Hospital, Free University of Berlin, Berlin, Germany
    Lancet 359:1187-93. 2002
  2. ncbi Infliximab in the treatment of active and severe ankylosing spondylitis
    J Brandt
    Medizinische Klinik und Poliklinik, Rheumatologie, Universitatsklinikum Benjamin Franklin, Berlin, Germany
    Clin Exp Rheumatol 20:S106-10. 2002
  3. pmc Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis
    J Brandt
    Department of Gastroenterology Rheumatology, Charite, Berlin, Germany
    Ann Rheum Dis 63:1438-44. 2004
  4. pmc Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide
    C Metzler
    Ann Rheum Dis 64:1798-800. 2005
  5. ncbi [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]
    J Brandt
    Klinikum Benjamin Franklin, Medizinische Klinik I, Rheumatologie, Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 62:264-73. 2003
  6. ncbi [Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis]
    J Brandt
    Rheumaklinik Bad Bramstedt, Innere Medizin, Rheumatologie, Immunologie, Oskar Alexander Str 26, 24576 Bad Bramstedt, Germany
    Z Rheumatol 63:203-10. 2004
  7. doi New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)
    J Sieper
    Medizinische Klinik I, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:784-8. 2009
  8. doi The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
    J Sieper
    Rheumatology, Medizinische Klinik I, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 68:ii1-44. 2009
  9. ncbi [Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12]
    H Haibel
    Deutsches Rheuma ForschungsZentrum, Berlin
    Z Rheumatol 63:393-401. 2004
  10. pmc Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis
    J Listing
    Deutsches Rheuma ForschungsZentrum, Berlin, Germany
    Ann Rheum Dis 63:1670-2. 2004

Collaborators

Detail Information

Publications47

  1. ncbi Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
    J Braun
    Department of Rheumatology, Benjamin Franklin Hospital, Free University of Berlin, Berlin, Germany
    Lancet 359:1187-93. 2002
    ..BACKGROUND Treatment options for patients with ankylosing spondylitis are few. We aimed to assess the effectiveness of infliximab, an antibody to tumour necrosis factor (TNF)-alpha, in treatment of such patients...
  2. ncbi Infliximab in the treatment of active and severe ankylosing spondylitis
    J Brandt
    Medizinische Klinik und Poliklinik, Rheumatologie, Universitatsklinikum Benjamin Franklin, Berlin, Germany
    Clin Exp Rheumatol 20:S106-10. 2002
    ..This article gives detailed information about current experience with the new treatment options in active and severe AS with anti-TNFalpha therapy...
  3. pmc Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis
    J Brandt
    Department of Gastroenterology Rheumatology, Charite, Berlin, Germany
    Ann Rheum Dis 63:1438-44. 2004
    ..To develop and compare candidate improvement criteria for anti-TNFalpha treatment in ankylosing spondylitis with optimal discriminating capacity between treatment and placebo...
  4. pmc Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide
    C Metzler
    Ann Rheum Dis 64:1798-800. 2005
  5. ncbi [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]
    J Brandt
    Klinikum Benjamin Franklin, Medizinische Klinik I, Rheumatologie, Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 62:264-73. 2003
    ..The purpose of this study was the validation of a German translation of the Bath Ankylosing Spondylitis Index (BASDAI)...
  6. ncbi [Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis]
    J Brandt
    Rheumaklinik Bad Bramstedt, Innere Medizin, Rheumatologie, Immunologie, Oskar Alexander Str 26, 24576 Bad Bramstedt, Germany
    Z Rheumatol 63:203-10. 2004
    ..In open trials these drugs also work in patients with uSpA. There is some hope now that the TNFalpha blocking agents could stop the development of AS in patients starting with uSpA...
  7. doi New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)
    J Sieper
    Medizinische Klinik I, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:784-8. 2009
    ..In the present report, a new approach for the development of IBP classification criteria is discussed...
  8. doi The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
    J Sieper
    Rheumatology, Medizinische Klinik I, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 68:ii1-44. 2009
    ..The focus of this handbook is on practicality, with many examples of MRI and x ray images, which will help to standardise not only patient care but also the design of clinical studies...
  9. ncbi [Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12]
    H Haibel
    Deutsches Rheuma ForschungsZentrum, Berlin
    Z Rheumatol 63:393-401. 2004
    ..Furthermore the data can be compared to the German standard population...
  10. pmc Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis
    J Listing
    Deutsches Rheuma ForschungsZentrum, Berlin, Germany
    Ann Rheum Dis 63:1670-2. 2004
    ..To analyse the impact of infliximab treatment on the number of hospital inpatient days and days of sick leave in patients with active ankylosing spondylitis (AS)...
  11. pmc Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Ann Rheum Dis 65:1147-53. 2006
    ..To assess the effect of sulfasalazine (SSZ) on inflammatory back pain (IBP) due to active undifferentiated spondyloarthritis (uSpA) or ankylosing spondylitis in patients with symptom duration <5 years...
  12. ncbi Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years
    J Braun
    Rheumatology Medical Center, Ruhrgebeit, Herne, Ruhr University, Bochum, Germany
    Rheumatology (Oxford) 44:670-6. 2005
    ..This report provides analyses from a 3-yr extension study, as a follow-up to both the 1- and 2-yr open label extensions of the original 3-month randomized controlled trial of infliximab in patients with AS...
  13. pmc Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Germany
    Ann Rheum Dis 64:1462-6. 2005
    ..It is unclear whether anti-TNF treatment affects chronic spinal changes in AS...
  14. pmc Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept
    M Rudwaleit
    Rheumatology, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 64:1305-10. 2005
    ....
  15. pmc Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis
    A Boonen
    Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, Netherlands
    Ann Rheum Dis 65:201-8. 2006
    ..To estimate the incremental cost-utility of etanercept and infliximab compared with usual care in active ankylosing spondylitis...
  16. ncbi Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab
    J Sieper
    Department of Rheumatology, Charite Medical School, Campus Benjamin Franklin, Berlin, Germany
    Rheumatology (Oxford) 44:1525-30. 2005
    ..It is not known whether spinal inflammation remains suppressed over time. Our objective was to assess spinal inflammation by MRI in AS patients after 2 yr of continuous infliximab treatment...
  17. pmc Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Ann Rheum Dis 64:229-34. 2005
    ....
  18. ncbi Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides
    J Braun
    Rheumazentrum Ruhrgebiet, Herne and University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany
    Scand J Rheumatol 34:178-90. 2005
    ..However, severe infections, including tuberculosis, have been reported. These can be largely prevented by appropriate screening. The benefits of anti-TNF therapy in AS seem to outweigh these shortcomings...
  19. ncbi Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis
    J Brandt
    Benjamin Franklin Hospital, Free University Berlin, Berlin, Germany
    Arthritis Rheum 48:1667-75. 2003
    ..This study was designed to investigate the efficacy of anti-TNFalpha therapy with etanercept, a 75-kd receptor fusion protein, in active AS...
  20. pmc Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept
    J Zou
    Rheumatology, Benjamin Franklin Klinikum, Deutsches Rheumaforschungszentrum, Berlin, Germany
    Ann Rheum Dis 62:561-4. 2003
    ..The precise mechanism of action, however, is not known...
  21. ncbi Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial
    J Braun
    Benjamin Franklin Hospital, Free University, Berlin, Germany
    Arthritis Rheum 48:2224-33. 2003
    ..The purpose of this study was to evaluate the efficacy and safety of infliximab treatment of AS for a 1-year period...
  22. ncbi Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Germany
    Rheumatology (Oxford) 46:1450-3. 2007
    ..The objective of this article was to study the effect of infliximab on structural changes in AS over 4 yrs...
  23. ncbi Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Arthritis Rheum 48:1126-36. 2003
    ....
  24. pmc Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis
    M Rudwaleit
    Rheumatology, Department of Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 63:665-70. 2004
    ..TNFalpha blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS)...
  25. ncbi Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Bochum, Germany
    Arthritis Rheum 53:856-63. 2005
    ....
  26. ncbi [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists]
    J Brandt
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany
    Z Rheumatol 62:218-27. 2003
    ..In expectation of the approval of infliximab and etanercept for the treatment of active AS international guidelines for initiation, monitoring and discontinuation of these agents have been recently proposed...
  27. pmc Differential impairment of spatial location memory in Huntington's disease
    J Brandt
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287 7218, USA
    J Neurol Neurosurg Psychiatry 76:1516-9. 2005
    ..To determine whether a differential impairment of spatial memory exists in Huntington's disease (HD)...
  28. pmc APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease
    S Cosentino
    Cognitive Neuroscience Division of the Gertrude H Sergievsky Center, Columbia University Medical Center, New York, NY 10032, USA
    Neurology 70:1842-9. 2008
    ..To determine whether APOE epsilon 4 predicts rate of cognitive change in incident and prevalent Alzheimer disease (AD)...
  29. ncbi [Effectiveness and safety of radium chloride in the treatment of ankylosing spondylitis. Results of an observational study]
    A Alberding
    Krankenhaus St Josef, Zentrum für Orthopädie und Rheumatologie, Wuppertal
    Z Rheumatol 65:245-51. 2006
    ..Nevertheless, a randomized placebo-controlled study should be performed in the near future in order to safeguard the level of evidence...
  30. ncbi The long-range transport of birch (Betula) pollen from Poland and Germany causes significant pre-season concentrations in Denmark
    C A Skjøth
    Department of Atmospheric Environment, National Environmental Research Institute, Roskilde, Denmark
    Clin Exp Allergy 37:1204-12. 2007
    ..Such episodes will in general occur out of the main pollen season. During this time, allergy patients are unprotected and high pollen concentrations will therefore have a full allergenic impact...
  31. ncbi Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease
    C W Zhu
    Geriatric Research, Education, and Clinical Center, Bronx VA Medical Center, 130 West Kingsbridge Road, Bronx, NY 10468, USA
    Neurology 67:998-1005. 2006
    ..To estimate long-term trajectories of direct cost of caring for patients with Alzheimer disease (AD) and examine the effects of patients' characteristics on cost longitudinally...
  32. pmc Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany
    Ann Rheum Dis 66:910-5. 2007
    ..These can be quantified by the modified Stokes Anklylosing Spondylitis Spinal Score (mSASSS). It is unknown which radiographic feature is most relevant for the assessment of change and the prediction of future damage in AS...
  33. ncbi Rheumatic manifestations of lymphoproliferative disorders
    U Kiltz
    Rheumazentrum Ruhrgebiet, St Josefs Krankenhaus, Herne, Germany
    Clin Exp Rheumatol 25:35-9. 2007
    ..The association between musculoskeletal features and lymphoproliferative disorders as well as the association of rheumatic diseases with an increased risk of malignancies is well-known...
  34. ncbi A seroepidemiological study of human cysticercosis in West Cameroon
    J P Nguekam
    University of Dschang, Dschang, Cameroon
    Trop Med Int Health 8:144-9. 2003
    ..13%) collected in the same region, we conclude that T. solium cysticercosis is an endemic, but overlooked public health problem in West Cameroon...
  35. ncbi The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis
    J Zochling
    Rheumazentrum Ruhrgebiet, St Josefs Krankenhaus, Landgrafenstrasse 15, 44652 Herne, Germany
    Rheumatology (Oxford) 44:1483-91. 2005
  36. pmc Conventional treatments for ankylosing spondylitis
    M Dougados
    Department of Rheumatology, Rene Descartes University, Hopital Cochin, 27 rue du Faobourg Saint Jacques, F 75014 Paris, France
    Ann Rheum Dis 61:iii40-50. 2002
    ..Thus, for patients with AS, the future of successful treatment lies in the development of pharmacological agents capable of both altering the disease course through intervention at sites of disease pathogenesis, and controlling symptoms...
  37. ncbi Improved cardiac function and quality of life following upgrade to dual chamber pacing after long-term ventricular stimulation
    C J Höijer
    Department of Cardiothoracic Surgery, Lund University Hospital, Lund, Sweden
    Eur Heart J 23:490-7. 2002
    ..This study aimed to investigate whether quality of life and cardiac function were affected by an upgrade to dual chamber pacing (DDDR or DDIR) following long-term ventricular stimulation...
  38. ncbi Treatment of active ankylosing spondylitis with pamidronate
    H Haibel
    Rheumatology (Oxford) 42:1018-20. 2003
  39. ncbi Taeniosis-cysticercosis in man and animals in the Sierra of Northern Ecuador
    R Rodriguez-Hidalgo
    Centro Internacional de Zoonosis, Universidad Central del Ecuador UC, PO Box 17 03 100, Quito, Ecuador
    Vet Parasitol 118:51-60. 2003
    ..saginata and 8 as T. solium. These data have been discussed in view of the epidemiology of human cysticercosis...
  40. pmc Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Ann Rheum Dis 63:1046-55. 2004
    ..To compare conventional radiography and magnetic resonance imaging (MRI) for detection of chronic changes in the spine of patients with ankylosing spondylitis (AS)...
  41. pmc Motor signs during the course of Alzheimer disease
    N Scarmeas
    Cognitive Neuroscience Division, Taub Institute for Research in Alzheimer s Disease and the Aging Brain, Gertrude H Sergievsky Center, and Department of Neurology, New York, NY 10032, USA
    Neurology 63:975-82. 2004
    ..Motor signs (MOSIs) are common in Alzheimer disease (AD) and may be associated with rates of cognitive decline, mortality, and cost of care...
  42. pmc Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany
    Ann Rheum Dis 64:730-4. 2005
    ..Magnetic resonance imaging (MRI) is increasingly used to detect inflammation in the spine of patients with ankylosing spondylitis (AS)...
  43. ncbi Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
    J Brandt
    Department of Gastroenterology Rheumatology, Charite, Medical University Berlin, Campus Benjamin Franklin, Germany
    Rheumatology (Oxford) 44:342-8. 2005
    ..The objective of the study was to assess the long-term efficacy and safety of etanercept over 1 yr, including discontinuation and readministration...
  44. pmc Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Germany
    Ann Rheum Dis 64:1141-4. 2005
    ....
  45. ncbi Neuropsychological predictors of dependency in patients with Alzheimer disease
    M Sarazin
    INSERM U 610 and Federation de Neurologie, Centre de Neuropsychologie, Hopital de la Salpetriere, 47 bd de l Hopital, 75013 Paris, France
    Neurology 64:1027-31. 2005
    ..To determine whether specific cognitive deficits can predict the progression of Alzheimer disease (AD)...
  46. pmc Motor signs predict poor outcomes in Alzheimer disease
    N Scarmeas
    Cognitive Neuroscience Division of the Taub Institute for Research in Alzheimer s Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA
    Neurology 64:1696-703. 2005
    ..To examine whether the presence of motor signs has predictive value for important outcomes in Alzheimer disease (AD)...
  47. ncbi Co-occurrence of spondyloarthropathy and connective tissue disease: development of Sjögren's syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitis
    J Brandt
    Medical Department I, Rheumatology, Benjamin Franklin Hospital, Free University of Berlin, Germany
    Clin Exp Rheumatol 20:80-4. 2002
    ..We describe the rare development of MCTD in an AS patient and report, for the first time, the onset of MCTD potentially triggered by sulfasalazine...